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Ghost Pills 
 
 
Background 
Some sustained-release formulations of oral medications are not fully digested. 
 
Purpose 
To alert clinicians to concerns that some patients and their care givers have about 
these medications. 
  
Case Report 
We prescribed a sustained-release form venlafaxine at a dose of 75mg once daily 
(Venlalic XL, DB Ashbourne Ltd) for a 71 year old man with Huntington’s disease 
who was suffering from depression and anxiety. The patient’s care giver expressed 
concern that the pills were being excreted, undigested, in his stool. She intrepidly 
isolated one pill and brought it to the clinic. Examination revealed an undigested pill 
casing looking very much like a fresh pill with a small hole through which the drug is 
designed to leach slowly (Figure A). Unlike a fresh pill, the retrieved pill was 
malleable to pressure (Figure B). The bisected pill was partially filled with insoluble 
matrix material into which the drug was originally dispersed (Figure C).  
 
Discussion 
Apparently undigested pills in the stool are known as “ghost pills.”(1-5) They are 
expected with certain sustained-release preparations, and their presence does not 
indicate that the drug itself is not being absorbed. Patients taking such preparations 
should be counselled in advance about ghost pills. 
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